| Pair Name | Gossypol, Trastuzumab | ||
| Phytochemical Name | Gossypol (PubChem CID: 3503 ) | ||
| Anticancer drug Name | Trastuzumab (PubChem CID: / ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Gossypol, Trastuzumab | |||
| Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Expression | PIK3CA | hsa5290 |
| Down-regulation | Expression | AKT1 | hsa207 | |
| In Vitro Model | SK-BR-3 | Breast adenocarcinoma | Homo sapiens (Human) | CVCL_0033 |
| MDA-MB-453 | Breast adenocarcinoma | Homo sapiens (Human) | CVCL_0418 | |
| Result | The trastuzumab/AT-101 combination may be a good candidate for patients with trastuzumab-resistant Her2-positive breast cancer and inhibition of the PI3K/AKT pathway may be one of the underlying mechanisms. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Trastuzumab in combination with AT-101 induces cytotoxicity and apoptosis in Her2 positive breast cancer cells. Future Oncol. 2020 Jan;16(3):4485-4495. doi: 10.2217/fon-2019-0521. | Click |
